Referenties

  1. Berden, F.A., et al., Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med, 2014. 72(8): p. 388-400.
  2. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). J Hepatol, 2020. 73(5): p. 1170-1218.
  3. AASLD/ISDA Recommendations for Testing, Managing and Treating Hepatitis C. August 2020; Available from: https://www.hcvguidelines.org/.
  4. van der Meer, A.J., et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama, 2012. 308(24): p. 2584-93.
  5. Arends, J.E., et al., Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med, 2011. 69(1): p. 43-9.
  6. Lamers, M.H., et al., Treatment of hepatitis C monoinfection in adults–Dutch national guidelines. Neth J Med, 2013. 71(7): p. 377-85.
  7. Boesecke, C., et al., Fueling the epidemic: low rates of spontaneous clearance of acute HCV coinfection, in Conference on Retroviruses and Opportunistic Infections. 2018: Boston.
  8. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017. 66(1): p. 153-194.
  9. Basu, P.P., et al., Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir Combination Therapy in the Management of Acute Hepatitis C: A Randomized Open Label Prospective Clinical Pilot Study. Slam C Study. Journal of Hepatology, 2016. 64(2): p. S806.
  10. Deterding, K., et al., Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis, 2017. 17(2): p. 215-222.
  11. Rockstroh, J.K., et al., Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. The Lancet Gastroenterology & Hepatology, 2017. 2(5): p. 347-353.
  12. Maan, R., et al., Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2016. 14(12): p. 1821-1830.e6.
  13. Resti, M., et al., Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. Bmj, 1998. 317(7156): p. 437-41.
  14. Back, D.J. and D.M. Burger, Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology, 2015. 149(6): p. 1315-7.
  15. Fontaine, H., et al., Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med, 2015. 373(19): p. 1886-8.
  16. Mogul, A., et al., Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia. Am J Health Syst Pharm, 2020. 77(6): p. 417-418.
  17. Lalanne, S., et al., Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. Ther Drug Monit, 2020. 42(2): p. 163-164.
  18. van Seyen, M., et al., Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. Int J Antimicrob Agents, 2020. 55(6): p. 105934.
  19. Fulco, P.P., R.K. Sterling, and S.R. Lavoie, Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus. Am J Health Syst Pharm, 2017. 74(21): p. 1761-1762.
  20. Jindracek, L. and J. Stark, Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube. J Pharm Pract, 2018. 31(5): p. 522-524.
  21. Huffman, V., et al., Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection. Am J Health Syst Pharm, 2021. 78(1): p. 36-40.
  22. Pijnenburg, D.W.M., et al., Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection. J Antimicrob Chemother, 2020. 75(9): p. 2661-2665.
  23. Yap, J.E., et al., Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube. J Clin Pharm Ther, 2018. 43(5): p. 730-732.
  24. Oberoi, R.K., et al., A Phase 1 Study to Evaluate the Effect of Crushing, Cutting Into Half, or Grinding of Glecaprevir/Pibrentasvir Tablets on Exposures in Healthy Subjects. J Pharm Sci, 2018. 107(6): p. 1724-1730.
  25. Tanaka, Y., R. Tateishi, and K. Koike, Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature. Clin J Gastroenterol, 2019. 12(6): p. 588-591.
  26. Marcos-Fosch, C., et al. Anti-epileptic drugs and hepatitis C therapy: Real-world experience. J Hepatol, 2021. 75(4): p. 984-985.
  27. Natali, K.M., Jimenez, H.R., Slim, J. When Coadministration Cannot Be Avoided: Real World Experience of Direct Acting Antivirals for the Treatment of Hepatitis C Virus Infection in Patients on First Generation Anticonvulsants. J Pharm Pract, 2022. 35(3): p. 495-499.